Appeal No. 1995-1989
Application 07/850,142
80. A method for aiding in diagnosing Alzheimer's Disease (“AD”) in a subject,
comprising the steps of:
a) contacting a biological fluid from said subject with a monoclonal antibody (“mAb”)
that binds specifically and to a statistically greater degree to a complementary acute
phase reactant antigen in a biological fluid obtained from a subject having AD than to an
antigenic site in a biological fluid from a subject not having AD, under conditions such that
an antigen-antibody binding complex forms between said mAb and said complementary
acute phase reactant antigen present in said fluid, if such an acute phase reactant antigen
is present therein;
b) detecting said binding complex;
c) correlating the formation of said binding complex with the presence of AD.
93. A mAb that binds specifically and to a statistically greater degree to a
complementary acute phase reactant antigen present in a biological fluid from a subject
having AD than to an antigenic site in a biological fluid from a subject not having AD.
105. A kit for aiding in diagnosing AD in a subject, comprising, in separate
compartments, a given amount of a mAb complementary to an acute phase reactant
antigen that is statistically elevated in a biological fluid from a subject having AD as
compared to a subject not having AD, and, optionally, labeled mAbs for detecting binding
between said mAb and said complementary acute phase reactant antigen.
The references relied on by the examiner are:
Cooper et al. (Cooper) 4,642,284 Feb. 10, 1987
Behan et al. (Behan), “Serum Proteins, Amyloid, and Alzheimer's Disease,” Abstract No.
96527h,Chemical Abstracts, Vol. 73, p. 178 (1970).
2
Page: Previous 1 2 3 4 5 6 7 8 9 Next
Last modified: November 3, 2007